Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene

Naoko Takebe, Shi Cheng Zhao, Debasis Adhikari, Shin Mineishi, Michel Sadelain, John Hilton, Michael Colvin, Debabrata Banerjee, Joseph Bertino

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The genetic transfer of drug resistance to hematopoietic cells is an attractive approach to overcoming myelosuppression caused by high-dose chemotherapy. Because cyclophosphamide (CTX) and methotrexate (MTX) are commonly used non-cross-resistant drugs, generation of dual drug resistance in hematopoietic cells that allows dose intensification may increase anti-tumor effects and circumvent the emergence of drug-resistant tumors. We constructed a retroviral vector containing both a human cytosolic ALDH-1 cDNA and a human doubly mutated DHFR cDNA (Phe22/Ser31; termed F/S in the description of constructs) to generate increased resistance to both CTX and MTX. Infection of NIH3T3 cells resulted in increased resistance to both 4-hydroperoxy-cyclophosphamide (4HC) (1.9 ± 0.1-fold) and MTX (73 ± 2.8-fold). Transduced human CD34+ enriched hematopoietic progenitor cells were also resistant to both 4HC and MTX by CFU-GM readout. Lethally irradiated mice transplanted with SFG-ALDH-IRES-F/S or mock-transduced bone marrow cells were treated with high-dose pulse CTX or high-dose CTX/MTX. Animals receiving marrow not transduced with ALDH-1 or mutated DHFR cDNA died from CTX or CTX/MTX toxicity, whereas mice transduced with ALDH-1 and mutated DHFR cDNA-containing marrow were able to tolerate the same doses of CTX or CTX/MTX treatment posttransplant. These data taken together indicate that ALDH-1 overexpression and mutant DHFR increased both 4HC and MTX resistance in vitro and in the in vivo mouse model. This construct may be useful for protecting patients from high-dose CTX- and MTX-induced myelosuppression.

Original languageEnglish (US)
Pages (from-to)88-96
Number of pages9
JournalMolecular Therapy
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

perfosfamide
Tetrahydrofolate Dehydrogenase
Methotrexate
Genes
Cyclophosphamide
Complementary DNA
Drug Resistance
Bone Marrow
aldehyde dehydrogenase 1
Granulocyte-Macrophage Progenitor Cells

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Genetics
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology

Cite this

Takebe, Naoko ; Zhao, Shi Cheng ; Adhikari, Debasis ; Mineishi, Shin ; Sadelain, Michel ; Hilton, John ; Colvin, Michael ; Banerjee, Debabrata ; Bertino, Joseph. / Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. In: Molecular Therapy. 2001 ; Vol. 3, No. 1. pp. 88-96.
@article{dc6ab830beee43f18e4bbee4143acb1b,
title = "Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene",
abstract = "The genetic transfer of drug resistance to hematopoietic cells is an attractive approach to overcoming myelosuppression caused by high-dose chemotherapy. Because cyclophosphamide (CTX) and methotrexate (MTX) are commonly used non-cross-resistant drugs, generation of dual drug resistance in hematopoietic cells that allows dose intensification may increase anti-tumor effects and circumvent the emergence of drug-resistant tumors. We constructed a retroviral vector containing both a human cytosolic ALDH-1 cDNA and a human doubly mutated DHFR cDNA (Phe22/Ser31; termed F/S in the description of constructs) to generate increased resistance to both CTX and MTX. Infection of NIH3T3 cells resulted in increased resistance to both 4-hydroperoxy-cyclophosphamide (4HC) (1.9 ± 0.1-fold) and MTX (73 ± 2.8-fold). Transduced human CD34+ enriched hematopoietic progenitor cells were also resistant to both 4HC and MTX by CFU-GM readout. Lethally irradiated mice transplanted with SFG-ALDH-IRES-F/S or mock-transduced bone marrow cells were treated with high-dose pulse CTX or high-dose CTX/MTX. Animals receiving marrow not transduced with ALDH-1 or mutated DHFR cDNA died from CTX or CTX/MTX toxicity, whereas mice transduced with ALDH-1 and mutated DHFR cDNA-containing marrow were able to tolerate the same doses of CTX or CTX/MTX treatment posttransplant. These data taken together indicate that ALDH-1 overexpression and mutant DHFR increased both 4HC and MTX resistance in vitro and in the in vivo mouse model. This construct may be useful for protecting patients from high-dose CTX- and MTX-induced myelosuppression.",
author = "Naoko Takebe and Zhao, {Shi Cheng} and Debasis Adhikari and Shin Mineishi and Michel Sadelain and John Hilton and Michael Colvin and Debabrata Banerjee and Joseph Bertino",
year = "2001",
month = "1",
day = "1",
doi = "https://doi.org/10.1006/mthe.2000.0236",
language = "English (US)",
volume = "3",
pages = "88--96",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. / Takebe, Naoko; Zhao, Shi Cheng; Adhikari, Debasis; Mineishi, Shin; Sadelain, Michel; Hilton, John; Colvin, Michael; Banerjee, Debabrata; Bertino, Joseph.

In: Molecular Therapy, Vol. 3, No. 1, 01.01.2001, p. 88-96.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene

AU - Takebe, Naoko

AU - Zhao, Shi Cheng

AU - Adhikari, Debasis

AU - Mineishi, Shin

AU - Sadelain, Michel

AU - Hilton, John

AU - Colvin, Michael

AU - Banerjee, Debabrata

AU - Bertino, Joseph

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The genetic transfer of drug resistance to hematopoietic cells is an attractive approach to overcoming myelosuppression caused by high-dose chemotherapy. Because cyclophosphamide (CTX) and methotrexate (MTX) are commonly used non-cross-resistant drugs, generation of dual drug resistance in hematopoietic cells that allows dose intensification may increase anti-tumor effects and circumvent the emergence of drug-resistant tumors. We constructed a retroviral vector containing both a human cytosolic ALDH-1 cDNA and a human doubly mutated DHFR cDNA (Phe22/Ser31; termed F/S in the description of constructs) to generate increased resistance to both CTX and MTX. Infection of NIH3T3 cells resulted in increased resistance to both 4-hydroperoxy-cyclophosphamide (4HC) (1.9 ± 0.1-fold) and MTX (73 ± 2.8-fold). Transduced human CD34+ enriched hematopoietic progenitor cells were also resistant to both 4HC and MTX by CFU-GM readout. Lethally irradiated mice transplanted with SFG-ALDH-IRES-F/S or mock-transduced bone marrow cells were treated with high-dose pulse CTX or high-dose CTX/MTX. Animals receiving marrow not transduced with ALDH-1 or mutated DHFR cDNA died from CTX or CTX/MTX toxicity, whereas mice transduced with ALDH-1 and mutated DHFR cDNA-containing marrow were able to tolerate the same doses of CTX or CTX/MTX treatment posttransplant. These data taken together indicate that ALDH-1 overexpression and mutant DHFR increased both 4HC and MTX resistance in vitro and in the in vivo mouse model. This construct may be useful for protecting patients from high-dose CTX- and MTX-induced myelosuppression.

AB - The genetic transfer of drug resistance to hematopoietic cells is an attractive approach to overcoming myelosuppression caused by high-dose chemotherapy. Because cyclophosphamide (CTX) and methotrexate (MTX) are commonly used non-cross-resistant drugs, generation of dual drug resistance in hematopoietic cells that allows dose intensification may increase anti-tumor effects and circumvent the emergence of drug-resistant tumors. We constructed a retroviral vector containing both a human cytosolic ALDH-1 cDNA and a human doubly mutated DHFR cDNA (Phe22/Ser31; termed F/S in the description of constructs) to generate increased resistance to both CTX and MTX. Infection of NIH3T3 cells resulted in increased resistance to both 4-hydroperoxy-cyclophosphamide (4HC) (1.9 ± 0.1-fold) and MTX (73 ± 2.8-fold). Transduced human CD34+ enriched hematopoietic progenitor cells were also resistant to both 4HC and MTX by CFU-GM readout. Lethally irradiated mice transplanted with SFG-ALDH-IRES-F/S or mock-transduced bone marrow cells were treated with high-dose pulse CTX or high-dose CTX/MTX. Animals receiving marrow not transduced with ALDH-1 or mutated DHFR cDNA died from CTX or CTX/MTX toxicity, whereas mice transduced with ALDH-1 and mutated DHFR cDNA-containing marrow were able to tolerate the same doses of CTX or CTX/MTX treatment posttransplant. These data taken together indicate that ALDH-1 overexpression and mutant DHFR increased both 4HC and MTX resistance in vitro and in the in vivo mouse model. This construct may be useful for protecting patients from high-dose CTX- and MTX-induced myelosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0034985885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034985885&partnerID=8YFLogxK

U2 - https://doi.org/10.1006/mthe.2000.0236

DO - https://doi.org/10.1006/mthe.2000.0236

M3 - Article

C2 - 11162315

VL - 3

SP - 88

EP - 96

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -